Current Status and Future Perspectives of Robotic Surgery for Esophagogastric Cancer in Asia
- 1Department of Surgery University Surgical Cluster, National University Health System Singapore Singapore
- 2Department of Surgical Oncology National University Cancer Institute National University Health System Singapore Singapore
- 3Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
Abstract
Robotic‐assisted surgery (RAS) has moved from an experimental adjunct to an increasingly established component of gastrointestinal (GI) oncological practice in parts of Asia, a region that carries a disproportionately high burden of gastric and esophageal cancer. Asian surgeons have been among the earliest and most prolific contributors to the clinical evidence base for robotic gastrectomy and robot‐assisted minimally invasive esophagectomy. This narrative review synthesizes evidence from randomized trials (including the ROBOT, RAMIE, and REVATE trials, and the ongoing MONA LISA [JCOG1907] study), multicenter prospective and propensity‐matched cohort studies, and recent meta‐analyses to critically appraise the efficacy, safety, cost, and future trajectory of RAS in Asia. Across multiple Korean, Japanese, and Chinese series, RG and RAMIE are associated with reduced short‐term morbidity, improved lymph node retrieval in technically demanding anatomic regions, and lower rates of recurrent laryngeal nerve injury compared with conventional laparoscopic or thoracoscopic approaches; however, much of the evidence on long‐term oncological outcomes remains retrospective or derived from propensity‐score analyses rather than mature randomized data, and results across studies are not always concordant. We argue that robotic surgery in Asia is best understood as passing through three overlapping transitions: technical and oncological validation, economic and educational democratization, and digital and telesurgical integration, each of which carries distinct and unresolved questions. We conclude that while RAS has demonstrably reshaped upper GI surgical practice in high‐volume Asian centers, its designation as a definitive regional standard of care should await longer‐term randomized outcomes, standardized credentialing, and more equitable deployment across the region.
Related
- Post-Treatment Surveillance to Detect Recurrent Disease in Esophagogastric Cancer: A Review of Current Practice and Future Perspectives
- Population-wide implementation of comprehensive cancer registration in Germany—overview article on current status quo and future perspectives
- Current status of various types of ICG contrast imaging in pediatric thoracic surgery
- Precision Perioperative Treatment for Resectable Non-Small Cell Lung Cancer: Current Status and Perspectives
- Current Status, Clinical Outcomes and Socioeconomic Challenges of Uniportal Video-Assisted Thoracoscopic Surgery in Japan Compared with Robot-Assisted Thoracic Surgery: A Narrative Review
BibTeX
@article{ang2026current,
title = {{Current Status and Future Perspectives of Robotic Surgery for Esophagogastric Cancer in Asia}},
author = {Jia Jun Ang and Jimmy Bok Yan So},
journal = {Annals of Gastroenterological Surgery},
year = {2026},
month = aug,
doi = {10.1002/ags3.70266},
url = {https://doi.org/10.1002/ags3.70266},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Current Status and Future Perspectives of Robotic Surgery for Esophagogastric Cancer in Asia
AU - Jia Jun Ang
AU - Jimmy Bok Yan So
PY - 2026
DA - 2026/08/17
JO - Annals of Gastroenterological Surgery
DO - 10.1002/ags3.70266
UR - https://doi.org/10.1002/ags3.70266
AB - Robotic‐assisted surgery (RAS) has moved from an experimental adjunct to an increasingly established component of gastrointestinal (GI) oncological practice in parts of Asia, a region that carries a disproportionately high burden of gastric and esophageal cancer. Asian surgeons have been among the earliest and most prolific contributors to the clinical evidence base for robotic gastrectomy and robot‐assisted minimally invasive esophagectomy. This narrative review synthesizes evidence from randomized trials (including the ROBOT, RAMIE, and REVATE trials, and the ongoing MONA LISA [JCOG1907] study), multicenter prospective and propensity‐matched cohort studies, and recent meta‐analyses to critically appraise the efficacy, safety, cost, and future trajectory of RAS in Asia. Across multiple Korean, Japanese, and Chinese series, RG and RAMIE are associated with reduced short‐term morbidity, improved lymph node retrieval in technically demanding anatomic regions, and lower rates of recurrent laryngeal nerve injury compared with conventional laparoscopic or thoracoscopic approaches; however, much of the evidence on long‐term oncological outcomes remains retrospective or derived from propensity‐score analyses rather than mature randomized data, and results across studies are not always concordant. We argue that robotic surgery in Asia is best understood as passing through three overlapping transitions: technical and oncological validation, economic and educational democratization, and digital and telesurgical integration, each of which carries distinct and unresolved questions. We conclude that while RAS has demonstrably reshaped upper GI surgical practice in high‐volume Asian centers, its designation as a definitive regional standard of care should await longer‐term randomized outcomes, standardized credentialing, and more equitable deployment across the region.
SN - 2475-0328
ER -